S
Stuart M. Flechner
Researcher at Cleveland Clinic
Publications - 173
Citations - 6701
Stuart M. Flechner is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 44, co-authored 170 publications receiving 6304 citations. Previous affiliations of Stuart M. Flechner include Cleveland Clinic Lerner College of Medicine & University of Cincinnati Academic Health Center.
Papers
More filters
Journal ArticleDOI
Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine.
Stuart M. Flechner,David A. Goldfarb,Charles S. Modlin,Jingyuan Feng,Venkatesh Krishnamurthi,Barbara Mastroianni,Kathy Savas,Daniel J. Cook,Andrew C. Novick +8 more
TL;DR: Calcineurin inhibitor drug avoidance with basiliximab induction and sirolimus provides comparable 1-year transplant outcomes, with significantly better renal function in primary renal allograft recipients.
Journal ArticleDOI
Single port transumbilical (E-NOTES) donor nephrectomy
Inderbir S. Gill,David Canes,Monish Aron,Georges-Pascal Haber,David A. Goldfarb,Stuart M. Flechner,Mahesh R. Desai,Jihad H. Kaouk,Mihir M. Desai +8 more
TL;DR: E-NOTES donor nephrectomy appears to have relevance and promise, especially for this typically younger, altruistic population, and natural orifices present an unprecedented opportunity for scar-free surgery.
Journal ArticleDOI
Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes.
Stuart M. Flechner,Sunil M. Kurian,Steven R. Head,Starlette M. Sharp,Thomas Whisenant,Jie Zhang,Jeffrey D. Chismar,Steve Horvath,Tony S. Mondala,Timothy J. Gilmartin,Daniel J. Cook,Steven A. Kay,John R. Walker,Daniel R. Salomon +13 more
TL;DR: A major challenge for kidney transplantation is balancing the need for immunosuppression to prevent rejection, while minimizing drug‐induced toxicities.
Journal ArticleDOI
Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
TL;DR: This work sought to review the impact of CNI‐sparing strategies in kidney, liver, and heart transplantation and found strategies to limit CNI exposure include CNI minimization, avoidance, and withdrawal.
Journal ArticleDOI
De Novo Kidney Transplantation Without Use of Calcineurin Inhibitors Preserves Renal Structure and Function at Two Years
Stuart M. Flechner,Sunil M. Kurian,Kim Solez,Daniel J. Cook,James T. Burke,Hank Rollin,Jennifer A. Hammond,Thomas Whisenant,Caroline Lanigan,Steven R. Head,Daniel R. Salomon +10 more
TL;DR: At 2 years the sirolimus‐treated recipients have better renal function, a diminished prevalence of CAN and down‐regulated expression of genes responsible for progression of CAN, which may provide for an alternative natural history with improved graft survival.